PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ACP issues updated Rapid, Living Practice Points on treating COVID-19 patients in outpatient settings

2023-09-18
(Press-News.org) Below please find a summary of a new article that will be published in the next issue of Annals of Internal Medicine. The summary is not intended to substitute for the full article as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------
ACP issues updated Rapid, Living Practice Points on treating COVID-19 patients in outpatient settings

Article: https://www.acpjournals.org/doi/10.7326/M23-1636 
Evidence Review: https://www.acpjournals.org/doi/10.7326/M23-1626

URL goes live when the embargo lifts
In an updated rapid, living practice points, the American College of Physicians (ACP) summarizes the latest evidence on the use of pharmacologic and biologic treatments of COVID-19 in the outpatient setting, specifically addressing the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. The paper is published in Annals of Internal Medicine.

 

As reports reveal a late-summer and fall rise of COVID-19 cases and the continued presence of dis- and misinformation about the transmission, vaccines, and treatments, it’s critical to identify evidence-based treatments for COVID-19 that continue to evolve with new data.  

 

Researchers for ACP reviewed two randomized controlled trials and 6 retrospective cohort studies to assess the benefits and harms of 22 different COVID-19 treatments. Treatments supported in the updated guidance include the consideration of molnupiravir or nirmatrelvir-ritonavir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within five days of the onset of symptoms and at a high risk for progressing to severe disease.

 

The practice points do not support the use of ivermectin or sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. In addition, there are 18 other treatments for which no eligible studies were identified for the Omicron variant. More research is needed about the effectiveness of treatments and if effectiveness varies by patient characteristics, immunity status, symptom duration, and disease severity of COVID-19 in the outpatient setting. 

 

Risk stratification is an important step before deciding the best approach to manage COVID-19 in the outpatient setting. The practice points note that the decision to initiate treatment for COVID-19 in the outpatient setting should be personalized and based on clinical judgment. Best practice is to use an informed decision-making approach with patients regarding potential treatment benefits and harms; patient characteristics (such as risk factors, comorbid conditions, and disease severity); patient preferences, and social determinants of health. Clinicians should review all medications and potential drug interactions before initiating outpatient treatment for COVID-19.

 

ACP’s Population Health and Medical Science Committee will maintain these practice points, as living by monitoring and assessing the impact of new evidence and updating as needed.

 

Media contacts: For an embargoed PDF, please contact Addison Dunlap at adunlap@acponline.org. To speak with someone from ACP, please contact Andrew Hachadorian at ahachadorian@acponline.org.

END


ELSE PRESS RELEASES FROM THIS DATE:

Promising gene-based approaches to repair lethal lung injury in the elderly from COVID-19, pneumonia, flu, sepsis

2023-09-18
Discovery from the lab of Youyang Zhao, PhD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago offers promising treatment approaches for acute respiratory distress syndrome (ARDS) in the elderly that can be caused by severe COVID-19, pneumonia, flu or sepsis. Currently there are no pharmacological or cell-based treatments for ARDS. Dr. Zhao’s research established that a gene called FOXM1 is important in the repair of blood vessel through regeneration of endothelial cells, which line the vessels of the lung. He found that aging impairs this gene’s expression, ...

Lifesaving addiction medications are rarely started following opioid overdose emergencies

2023-09-18
Could future opioid overdoses, fatalities and other harms of opioid addiction be prevented if hospital emergency departments made better use of effective medications for opioid addiction? A team of University of Michigan researchers thinks so.  Led by Thuy Nguyen of U-M's School of Public Health, the researchers analyzed national Medicaid claims data of patients ages 12 to 64 treated at U.S. emergency departments for opioid overdoses in 2018. They focused on ED visits for opioid overdose and the rate of initiation of FDA-approved medications for opioid addiction, including buprenorphine, methadone and extended release naltrexone.  The ...

Disparities in flu vaccine uptake persist in people with kidney disease

Disparities in flu vaccine uptake persist in people with kidney disease
2023-09-18
Among adults with chronic kidney disease (CKD) enrolled in the Chronic Renal Insufficiency Cohort (CRIC), young age, Black race, and low levels of education and income were associated with lower likelihood of getting an annual flu shot. Identifying risk factors for not receiving a flu vaccine (“non-vaccination”) in people living with kidney disease, who are at risk of flu and its complications, could inform strategies for improving vaccine uptake. In this study published in the American Journal of Kidney Diseases (AJKD), researchers led by Junichi Ishigami examined whether demographic factors, social ...

A suit of armor for cancer-fighting cells

2023-09-18
In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients’ T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer. Six CAR T cell therapies have secured FDA approval, and several more are in the pipeline. However, these therapies come with severe and potentially lethal side effects, namely cytokine release syndrome (CRS) and neurotoxicity. These drawbacks manifest as a range of symptoms—from high fever and vomiting to multiple ...

Dana-Farber leads adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma

2023-09-18
EMBARGOED: September 18, 2023 4PM EST CONTACT:  Nicole Oliverio, nicole_oliverio@dfci.harvard.edu, 617-257-0454 Boston – An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that ...

New research highlights importance of equity in education

New research highlights importance of equity in education
2023-09-18
A new study looks at the impact of learning environments on the academic success of racialized students. Compared to their peers, these students feel they have less control in their academic environment, less confidence and self-efficacy in their academic abilities, and weaker connections to other students and professors. The University of Ottawa study underscores that higher education institutions must recognize and address the specific needs of their racialized student communities and create inclusive learning environments that better meet these needs. Failing to do so could affect the overall psychological well-being and academic performance ...

Cell therapy can reduce risk of death from COVID-19 by 60%, study shows

2023-09-18
The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States. Their findings are reported in an article published in the journal Frontiers in Immunology. The review covers 195 clinical trials of advanced cell therapies targeting COVID-19 that were conducted in 30 countries between January 2020 and December 2021, as well as 26 trials with outcomes published by July 2022. Cell therapy has come into increasingly frequent use in recent years ...

The pace of climate-driven extinction is accelerating, a UArizona-led study shows

The pace of climate-driven extinction is accelerating, a UArizona-led study shows
2023-09-18
Climate change is causing extinctions at an increasing rate, a new study by the University of Arizona researchers shows. They surveyed populations of the Yarrow's spiny lizard in 18 mountain ranges in southeastern Arizona and analyzed the rate of climate-related extinction over time. "The magnitude of extinction we found over the past seven years was similar to that seen in other studies that spanned almost 70 years," said John J. Wiens, a professor in the Department of Ecology and Evolutionary Biology at UArizona, ...

Nuclear medicine treatment cures lethal form of ovarian cancer in preclinical setting

Nuclear medicine treatment cures lethal form of ovarian cancer in preclinical setting
2023-09-18
Reston, VA—A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the HER2 protein, which is commonly expressed in ovarian cancer, the therapy (anti-HER2 225Ac-PRIT) is a potential treatment for the otherwise incurable disease. This research was published in the September issue of The Journal of Nuclear Medicine. Epithelial ovarian cancer is the most lethal ovarian cancer and frequently presents as advanced-stage disease, ...

Gene links exercise endurance, cold tolerance, and cellular maintenance in flies

2023-09-18
EMBARGOED FOR RELEASE UNTIL September 18, 2023 at 3:00 PM U.S. Eastern time As the days get shorter and chillier in the northern hemisphere, those who choose to work out in the mornings might find it harder to get up and running. A new study in PNAS identifies a protein that, when missing, makes exercising in the cold that much harder—that is, at least in fruit flies. A team from University of Michigan Medical School and Wayne State University School of Medicine discovered the protein in flies, which they named Iditarod after the famous long distance dog sled across Alaska, while studying metabolism and the effect of stress on the body. They were particularly ...

LAST 30 PRESS RELEASES:

Osteoporosis treatment benefits people older than 80

Consuming more protein may protect patients taking anti-obesity drug from muscle loss

Thyroid treatment may improve gut health in people with hypothyroidism

Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss

High blood sugar may have a negative impact on men’s sexual health

Emotional health of parents tied to well-being of children with growth hormone deficiency

Oxytocin may reduce mood changes in women with disrupted sleep

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury

Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1

Single-cell RNA sequencing reveals Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic ce

Acta Pharmaceutica Sinica B Volume 15, Issue 7 Publishes

New research expands laser technology

Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain

A high clinically translatable strategy to anti-aging using hyaluronic acid and silk fibroin co-crosslinked hydrogels as dermal regenerative fillers

Mount Sinai researchers uncover differences in how males and females change their mind when reflecting on past mistakes

CTE and normal aging are difficult to distinguish, new study finds

Molecular arms race: How the genome defends itself against internal enemies

Tiny chip speeds up antibody mapping for faster vaccine design

KTU experts reveal why cultural heritage is important for community unity

More misfolded proteins than previously known may contribute to Alzheimer’s and dementia

“Too much going on”: Autistic adults overwhelmed by non-verbal social cues

What’s driving America’s deep freezes in a warming world?

A key role of brain protein in learning and memory is deciphered by scientists

Heart attacks don’t follow a Hollywood script

Erin M. Schuman wins 2026 Nakasone Award for discovery on neural synapse function and change during formation of memories

Global ocean analysis could replace costly in-situ sound speed profiles in seafloor positioning, study finds

Power in numbers: Small group professional coaching reduces rates of physician burnout by nearly 30%

Carbon capture, utilization, and storage: A comprehensive review of CCUS-EOR

New high-temperature stable dispersed particle gel for enhanced profile control in CCUS applications

[Press-News.org] ACP issues updated Rapid, Living Practice Points on treating COVID-19 patients in outpatient settings